Autopsy report · NCT00527124

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

“Closure was recommended by CTEP due to slow accrual.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 6 years before it stopped.
• 57 participants enrolled.
• Results were posted on the registry 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

National Cancer Institute (NCI)

Sponsor type

US National Institutes of Health

Conditions

Adenocarcinoma of the Prostate; Stage IV Prostate Cancer

Interventions

cediranib maleate; docetaxel; prednisone; laboratory biomarker analysis

Participants

57

Sites

4

Countries

United States

Trials that died the same way

• HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
  “slow accrual \& early closure” (64% match in meaning)
• Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning
  “Closed early due to slow accrual.” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.